Literature DB >> 17429342

Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency.

N J Brown1, J Bradford, Z Wang, W Lea, L Ma, J Ma, D E Vaughan, A B Fogo.   

Abstract

Angiotensin (Ang) II stimulates plasminogen activator inhibitor-1 (PAI-1) expression in many cell types by mechanisms that are cell-type specific. We measured effects of Ang II or norepinephrine on PAI-1 expression in wild type (WT) and Ang type-1a receptor knockout mice (AT(1a)-/-) in the presence or absence of the non-specific AT(1) antagonist losartan. Ang II and norepinephrine increased systolic blood pressure equally, whereas losartan decreased the pressor response of the former but not the latter in WT mice. In AT(1a)-/- mice, baseline systolic blood pressure was lower with no effect of Ang II, norepinephrine, or losartan. Ang II stimulated PAI-1 expression in the heart, aorta, and kidney and markedly in the liver of WT mice. In AT(1a)-/- mice, Ang II-stimulated PAI-1 was significantly attenuated compared with the WT in the heart and aorta but significantly enhanced in the kidney. Losartan decreased the induction in the aorta and liver of WT, and in the kidney and liver of AT(1a)-/- mice. Norepinephrine increased PAI-1 expression in WT heart and aorta, and in AT(1a)-/- heart, kidney, and liver with no effect of losartan. Renal PAI-1 expression correlated with AT(1b) receptor mRNA. We conclude that Ang II stimulates PAI-1 expression in part through the AT(1b) receptor in the kidney and liver. Further, norepinephrine induces PAI-1 expression in vivo with AT(1a) receptor deficiency modulating the effect.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17429342     DOI: 10.1038/sj.ki.5002268

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.

Authors:  William B Lea; Eun Soo Kwak; James M Luther; Susan M Fowler; Zuofei Wang; Ji Ma; Agnes B Fogo; Nancy J Brown
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

2.  Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta.

Authors:  James M Luther; Zuofei Wang; Ji Ma; Natalia Makhanova; Hyung-Suk Kim; Nancy J Brown
Journal:  Endocrinology       Date:  2008-12-23       Impact factor: 4.736

Review 3.  The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.

Authors:  Hunjoo Ha; Eun Y Oh; Hi B Lee
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

4.  An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease.

Authors:  Chunyan Gu; Jiandong Zhang; Nancy A Noble; Xiao-Rong Peng; Yufeng Huang
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-10

5.  Nocturnal light exposure alters hepatic Pai-1 expression by stimulating the adrenal pathway in C3H mice.

Authors:  Yoshiki Aoshima; Hiroyuki Sakakibara; Taka-aki Suzuki; Shunsuke Yamazaki; Kayoko Shimoi
Journal:  Exp Anim       Date:  2014

Review 6.  Focused Review of Perioperative Care of Patients with Pulmonary Hypertension and Proposal of a Perioperative Pathway.

Authors:  Jochen Steppan; Natalia Diaz-Rodriguez; Viachaslau M Barodka; Daniel Nyhan; Erica Pullins; Traci Housten; Rachel L Damico; Stephen C Mathai; Paul M Hassoun; Dan E Berkowitz; Bryan G Maxwell; Todd M Kolb
Journal:  Cureus       Date:  2018-01-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.